Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial
Authors:
- 14 March 2022
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (12) , 3117-3126
Abstract
Background Rituximab and tacrolimus are therapies reserved for patients with frequently relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid-sparing agents. Given their toxicities, demonstrating non-inferiority of rituximab to tacrolimus may enable choice between these medications. Methods This investigator-initiated, single-center, open-label, pilot randomized controlled trial examined the non-inferiority of two doses of intravenous (IV) rituximab given one-week apart to oral therapy with tacrolimus (1:1 allocation), in maintaining sustained remission over 12 months follow-up, in patients with difficult-to-treat steroid-sensitive nephrotic syndrome, defined as frequently relapsing or steroid-dependent disease that had failed ≥ 2 steroid-sparing strategies. Secondary outcomes included frequency of relapses, proportion with frequent relapses, time to relapse and frequent relapses, and adverse events (CTRI/2018/11/016342). Results Baseline characteristics were comparable for 41 patients randomized to receive rituximab (n = 21) or tacrolimus (n = 20). While 55% of patients in each limb were in sustained remission at 1 year, non-inferiority of rituximab to tacrolimus was not demonstrated (mean difference 0%; 95% CI – 30.8%, 30.8%; non-inferiority limit – 20%; P = 0.50). Frequent relapses were more common in patients administered rituximab compared to tacrolimus (risk difference 30%, 95% CI 7.0, 53.0, P = 0.023). Both groups showed similar reductions in relapse rates and prednisolone use. Common adverse events were infusion-related with rituximab and gastrointestinal symptoms with tacrolimus. Conclusions Therapy with rituximab was not shown to be non-inferior to 12-months treatment with tacrolimus in maintaining remission in patients with difficult-to-treat steroid-sensitive nephrotic syndrome. Frequent relapses were more common with rituximab. While effective, both agents require close monitoring for adverse events. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.Keywords
Funding Information
- Department of Biotechnology, Government of West Bengal (BT/PR11030/MED/ 30/1644/2016)
- Indian Council of Medical Research (5/7/1090/2013-RHN)
- Intas Pharmaceuticals, Ahmedabad, India
This publication has 38 references indexed in Scilit:
- Rituximab therapy in nephrotic syndrome: implications for patients' managementNature Reviews Nephrology, 2013
- Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndromeIndian Journal of Nephrology, 2013
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndromePediatric Nephrology, 2012
- Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndromePediatric Nephrology, 2011
- Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2011
- Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndromeJournal of Clinical Pathology, 2011
- Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2010
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Safety of tacrolimus in patients with rheumatoid arthritis: long-term experienceRheumatology, 2004